Background: The aim of the study was to evaluate the feasibility and efficacy of a non-myeloablative regimen to achieve complete donor chimerism after stem cell transplantation (SCT) in patients with metastatic solid tumors.Patients and methods: Seven patients with renal cell carcinoma (RCC), 3 with colorectal carcinoma and 1 with soft tissue sarcoma received an allogeneic SCT after fludarabine ( 90 mg/m(2)) and TBI 200 cGy.Results: At day 30, median donor chimerism was 94%. Regression of tumor metastases has been observed in 1 patient with RCC. Overall, 8 patients (73%) died from progressive disease ( median progression-free survival 3.7 months) and 1 (9%) from treatment-related complications; 2 patients were alive 152 and 862 days after transplantation.Conclusions: Our preliminary results suggest that non-myeloablative SCT for metastatic solid tumors is feasible, although may lead to durable responses in a minority of patients. Careful patient selection seems to be mandatory in this transplant setting.
Busca, A., Novarino, A., De Fabritiis, P., Picardi, A., Zeuli, M., Locatelli, F., Bertetto, O., Falda, M., Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors, <<HEMATOLOGY>>, 2006; 11 (3): 171-177. [doi:10.1080/10245330600775253] [https://hdl.handle.net/10807/259049]
Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors
Locatelli, Franco;
2006
Abstract
Background: The aim of the study was to evaluate the feasibility and efficacy of a non-myeloablative regimen to achieve complete donor chimerism after stem cell transplantation (SCT) in patients with metastatic solid tumors.Patients and methods: Seven patients with renal cell carcinoma (RCC), 3 with colorectal carcinoma and 1 with soft tissue sarcoma received an allogeneic SCT after fludarabine ( 90 mg/m(2)) and TBI 200 cGy.Results: At day 30, median donor chimerism was 94%. Regression of tumor metastases has been observed in 1 patient with RCC. Overall, 8 patients (73%) died from progressive disease ( median progression-free survival 3.7 months) and 1 (9%) from treatment-related complications; 2 patients were alive 152 and 862 days after transplantation.Conclusions: Our preliminary results suggest that non-myeloablative SCT for metastatic solid tumors is feasible, although may lead to durable responses in a minority of patients. Careful patient selection seems to be mandatory in this transplant setting.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
